AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and resp… Read more
AstraZeneca Pharma India Limited (ASTRAZEN) - Total Liabilities
Latest total liabilities as of September 2025: ₹8.16 Billion INR
Based on the latest financial reports, AstraZeneca Pharma India Limited (ASTRAZEN) has total liabilities worth ₹8.16 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AstraZeneca Pharma India Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how AstraZeneca Pharma India Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AstraZeneca Pharma India Limited Competitors by Total Liabilities
The table below lists competitors of AstraZeneca Pharma India Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Internacional de Cerámica S.A.B. de C.V
MX:CERAMICB
|
Mexico | MX$15.32 Billion |
|
Armada Hflr Pr
NYSE:AHH
|
USA | $1.77 Billion |
|
Electrolux Professional AB (publ)
OTCGREY:ECTXF
|
USA | $7.52 Billion |
|
Veken Elite
SHG:600152
|
China | CN¥1.10 Billion |
|
Optics Technology Holding Co Ltd
SHE:300489
|
China | CN¥3.41 Billion |
|
Gruppo MutuiOnline S.p.A.
LSE:0O2B
|
UK | €887.83 Million |
|
Djerriwarrh Investments Ltd
AU:DJW
|
Australia | AU$75.50 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down AstraZeneca Pharma India Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.51 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AstraZeneca Pharma India Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AstraZeneca Pharma India Limited (2005–2025)
The table below shows the annual total liabilities of AstraZeneca Pharma India Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹7.48 Billion | +104.25% |
| 2024-03-31 | ₹3.66 Billion | -7.59% |
| 2023-03-31 | ₹3.96 Billion | +14.78% |
| 2022-03-31 | ₹3.45 Billion | +8.36% |
| 2021-03-31 | ₹3.19 Billion | -6.84% |
| 2020-03-31 | ₹3.42 Billion | +31.00% |
| 2019-03-31 | ₹2.61 Billion | +22.19% |
| 2018-03-31 | ₹2.14 Billion | +8.27% |
| 2017-03-31 | ₹1.97 Billion | -20.99% |
| 2016-03-31 | ₹2.50 Billion | -4.27% |
| 2015-03-31 | ₹2.61 Billion | +6.90% |
| 2014-03-31 | ₹2.44 Billion | +18.24% |
| 2013-03-31 | ₹2.06 Billion | +35.05% |
| 2012-03-31 | ₹1.53 Billion | +18.46% |
| 2011-03-31 | ₹1.29 Billion | +44.37% |
| 2010-03-31 | ₹893.48 Million | -48.24% |
| 2009-03-31 | ₹1.73 Billion | +98.61% |
| 2008-03-31 | ₹869.08 Million | -11.43% |
| 2007-03-31 | ₹981.27 Million | +103.35% |
| 2006-03-31 | ₹482.54 Million | -32.88% |
| 2005-03-31 | ₹718.96 Million | -- |